Arcturus Therapeutics Holdings (ARCT) Capital Expenditures (2018 - 2025)

Arcturus Therapeutics Holdings' Capital Expenditures history runs 8 years deep, the most recent figure standing at -$88000.0 for Q4 2025.

• Quarterly Capital Expenditures changed N/A year-over-year to -$88000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $93000.0 (down 82.94% YoY) and the FY2025 annual result came in at $230000.0, down 64.51% from the prior year.
• Capital Expenditures was -$88000.0 for Q4 2025 at Arcturus Therapeutics Holdings, down from $181000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $2.2 million in Q3 2022 and bottomed at -$3.3 million in Q4 2022.
• A 5-year average of $244722.2 and a median of $159000.0 in 2025 frame the typical range for Capital Expenditures.
• Peak annual rise in Capital Expenditures reached 1688.98% in 2022, while the deepest fall reached 47700.0% in 2022.
• Arcturus Therapeutics Holdings' Capital Expenditures stood at -$7000.0 in 2021, then tumbled by 47700.0% to -$3.3 million in 2022, then jumped by 126.15% to $875000.0 in 2023, then slumped by 90.86% to $80000.0 in 2024, then sank by 210.0% to -$88000.0 in 2025.
• Business Quant data shows ARCT's Capital Expenditures at -$88000.0 in Q4 2025, $181000.0 in Q3 2025, and $137000.0 in Q1 2025.